Is NCT07490067 recruiting in Ann Arbor, MI?

Yes, NCT07490067 is currently recruiting participants at its Ann Arbor, MI location. This heart failure with reduced ejection fraction clinical trial is actively enrolling qualified participants.

Is participation in this Ann Arbor clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Heart Failure With Reduced Ejection Fraction Clinical Trial in Ann Arbor, MI

Q: How do I join the heart failure with reduced ejection fraction clinical trial in Ann Arbor?

To join this clinical trial in Ann Arbor, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Heart Failure With Reduced Ejection Fraction Study in Ann Arbor

The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics. Participants will have the beta-blocker (BB) polygenic score calculated from genotype data. The score will be used to stratify the patients in the low and high polygenic score groups in the study. The hypotheses for this trial are: * HFrEF patients with high polygenic score will have weaker cardiovascular responses to metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score have lower steady-state plasma concentrations of metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score require higher metoprolol succinate plasma concentrations to achieve similar cardiovascular effects as those with low polygenic score.

Sponsor: University of Michigan

Who Can Participate

Inclusion Criteria

Heart Failure with Reduced Ejection Fraction (HFrEF)

Has not taken a beta-blocker within the past 6 months (preferred), or if needed to meet enrollment target, patients that have not taken a beta-blocker in the past 3 months, or only taken a low dose of beta-blocker within the past 6 months (i.e., \< 50% of the guideline-recommended HFrEF target dose, or for beta-blockers that are not approved for HFrEF, \<50% of the maximum dose)

Genetic data already available to calculate the polygenic score (e.g., through participation in the Michigan Genomics Initiative (MGI) or other genetic tests) or willingness to provide a deoxyribonucleic acid (DNA) sample for genetic analysis

Has been prescribed a stable dose (including no dose) of angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), ARB-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 (SGLT-2) inhibitor, or mineralocorticoid receptor antagonist (MRA) for at least the past 4 weeks

Has been prescribed a stable dose (including no dose) of diuretic(s) for at least the past 2 weeks

For women of child-bearing potential: the participant is willing to perform a pregnancy test and use a highly effective contraceptive method for at least 4 weeks prior to the start of metoprolol treatment, during the entire metoprolol treatment period, and for at least 5 days after the discontinuation of metoprolol treatment

Ability to understand and willing to sign a written informed consent

Exclusion Criteria

Prior heart transplant or left ventricular assist device (LVAD) or planned within treatment period

Planned implantation of a pacemaker or Cardiac Resynchronization Therapy (CRT) during treatment period

Patients with a pacemaker that does not allow their heart rate to change in response to exercise per protocol

Systolic blood pressure \< 95 millimeters of mercury (mmHg)

Heart rate \< 60 beats per minute

Second (Mobitz II)- or third-degree heart block

Cardiogenic shock

Patients with acute decompensated heart failure requiring current hospitalization or immediate medical intervention.

Sick sinus syndrome

Pheochromocytoma

Known hypersensitivity to the metoprolol succinate oral tablet used in the trial

Hypertrophic obstructive cardiomyopathy

Active myocarditis

Acute coronary syndrome within the past month

Active or uncorrected severe mitral or aortic valvular dysfunction

Patients with known severe congenital heart disease per protocol

Child-Pugh Class C liver disease

Patients with end-stage renal disease (ESRD) requiring hemodialysis

Concomitant disease that prohibits participating in Cardiopulmonary Exercise Test (CPET) per protocol

Concomitant disease with expected survival less than the duration of the study (e.g., metastatic cancer)

Current or planned treatment with cardiotoxic medications, including interferons and the cancer therapies per protocol

Concurrent participation in another clinical trial that may affect participant safety or validity of data collected in this clinical trial

Inability to take oral medication

Unwilling or unlikely to adhere to the study procedures, as determined at the discretion of the study team, including but not limited to the following reasons:

Psychiatric illness or other comorbidities

Substance abuse

Social or logistical circumstances

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ann Arbor?

Yes, this clinical trial (NCT07490067) has an active research site in Ann Arbor, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Failure With Reduced Ejection Fraction Treatment Options in Ann Arbor, MI

If you're searching for heart failure with reduced ejection fraction treatment options in Ann Arbor, MI, this clinical trial (NCT07490067) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ann Arbor research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced heart failure with reduced ejection fraction specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart failure with reduced ejection fraction clinical trials near you to find additional studies recruiting in your area.

Heart Failure With Reduced Ejection Fraction Clinical Trial in Ann Arbor, MI

Expert Care in Ann Arbor

IRB Approved

No-Cost Care

Apply for This Ann Arbor Location

Why Participate?

Simple Process